Literature DB >> 25798678

Pre-transplant sirolimus might improve the outcome of haploidentical peripheral blood stem cell transplantation with post-transplant cyclophosphamide for patients with severe aplastic anemia.

S R Jaiswal1, S Chatterjee2, S Mukherjee3, K Ray4, S Chakrabarti1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25798678     DOI： 10.1038/bmt.2015.50

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  11 in total

1.  Good outcome of haploidentical hematopoietic SCT as a salvage therapy in children and adolescents with acquired severe aplastic anemia.

Authors:  Z Wang; X Zheng; H Yan; D Li; H Wang
Journal:  Bone Marrow Transplant       Date:  2014-08-18       Impact factor: 5.483

2.  NK-dependent DC maturation is mediated by TNFalpha and IFNgamma released upon engagement of the NKp30 triggering receptor.

Authors:  Massimo Vitale; Mariella Della Chiesa; Simona Carlomagno; Daniela Pende; Maurizio Aricò; Lorenzo Moretta; Alessandro Moretta
Journal:  Blood       Date:  2005-03-22       Impact factor: 22.113

3.  A novel protocol for haploidentical hematopoietic SCT without in vitro T-cell depletion in the treatment of severe acquired aplastic anemia.

Authors:  L P Xu; K Y Liu; D H Liu; W Han; H Chen; Y H Chen; X H Zhang; Y Wang; F R Wang; J Z Wang; X J Huang
Journal:  Bone Marrow Transplant       Date:  2012-05-28       Impact factor: 5.483

4.  Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide.

Authors:  P V O'Donnell; L Luznik; R J Jones; G B Vogelsang; M S Leffell; M Phelps; P Rhubart; K Cowan; S Piantados; E J Fuchs
Journal:  Biol Blood Marrow Transplant       Date:  2002       Impact factor: 5.742

5.  Long-term outcome of HLA-haploidentical hematopoietic SCT without in vitro T-cell depletion for adult severe aplastic anemia after modified conditioning and supportive therapy.

Authors:  L Gao; Y Li; Y Zhang; X Chen; L Gao; C Zhang; Y Liu; P Kong; Q Wang; Y Su; C Wang; S Wang; B Li; A Sun; X Du; D Zeng; J Li; H Liu; X Zhang
Journal:  Bone Marrow Transplant       Date:  2014-01-27       Impact factor: 5.483

6.  Thrombotic microangiopathy associated with sirolimus level after allogeneic hematopoietic cell transplantation with tacrolimus/sirolimus-based graft-versus-host disease prophylaxis.

Authors:  Sepideh Shayani; Joycelynne Palmer; Tracey Stiller; Xueli Liu; Sandra H Thomas; Tam Khuu; Pablo M Parker; Samer K Khaled; Stephen J Forman; Ryotaro Nakamura
Journal:  Biol Blood Marrow Transplant       Date:  2012-10-15       Impact factor: 5.742

7.  Sirolimus and post transplant Cy synergistically maintain mixed chimerism in a mismatched murine model.

Authors:  C D Fitzhugh; R P Weitzel; M M Hsieh; O A Phang; C Madison; L Luznik; J D Powell; J F Tisdale
Journal:  Bone Marrow Transplant       Date:  2013-04-22       Impact factor: 5.483

8.  Nonmyeloablative peripheral blood haploidentical stem cell transplantation for refractory severe aplastic anemia.

Authors:  Jennifer Clay; Austin G Kulasekararaj; Victoria Potter; Francesco Grimaldi; Donal McLornan; Kavita Raj; Hugues de Lavallade; Michelle Kenyon; Antonio Pagliuca; Ghulam J Mufti; Judith C W Marsh
Journal:  Biol Blood Marrow Transplant       Date:  2014-07-10       Impact factor: 5.742

9.  Allogeneic stem cell transplantation for children with acquired severe aplastic anaemia: a retrospective study by the Viva-Asia Blood and Marrow Transplantation Group.

Authors:  Jing Chen; Vincent Lee; Cheng Juan Luo; Alan Kwok Shing Chiang; Suradej Hongeng; Poh Lin Tan; Ah Moy Tan; Kleebsabai Sanpakit; Chun Fu Li; Anselm Chi-wai Lee; Hsin Chieh Chua; Yasuhiro Okamoto
Journal:  Br J Haematol       Date:  2013-06-05       Impact factor: 6.998

10.  Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide.

Authors:  Christopher G Kanakry; Sudipto Ganguly; Marianna Zahurak; Javier Bolaños-Meade; Christopher Thoburn; Brandy Perkins; Ephraim J Fuchs; Richard J Jones; Allan D Hess; Leo Luznik
Journal:  Sci Transl Med       Date:  2013-11-13       Impact factor: 17.956
View more
  6 in total

1.  Analysis of allogeneic hematopoietic stem cell transplantation with high-dose cyclophosphamide-induced immune tolerance for severe aplastic anemia.

Authors:  Zhi Guo; Hong-Yan Gao; Tian-Yan Zhang; Xiao-Dong Liu; Kai Yang; Jing-Xing Lou; Xue-Peng He; Yuan Zhang; Peng Chen; Hui-Ren Chen
Journal:  Int J Hematol       Date:  2016-10-05       Impact factor: 2.490

Review 2.  Evolving hematopoietic stem cell transplantation strategies in severe aplastic anemia.

Authors:  Andrew C Dietz; Giovanna Lucchini; Sujith Samarasinghe; Michael A Pulsipher
Journal:  Curr Opin Pediatr       Date:  2016-02       Impact factor: 2.856

3.  Hemophagocytic syndrome following haploidentical peripheral blood stem cell transplantation with post-transplant cyclophosphamide.

Authors:  Sarita Rani Jaiswal; Aditi Chakrabarti; Sumita Chatterjee; Sneh Bhargava; Kunal Ray; Suparno Chakrabarti
Journal:  Int J Hematol       Date:  2015-11-30       Impact factor: 2.490

Review 4.  Haploidentical Donor Bone Marrow Transplantation for Severe Aplastic Anemia.

Authors:  Amy E DeZern; Robert A Brodsky
Journal:  Hematol Oncol Clin North Am       Date:  2018-05-28       Impact factor: 3.722

5.  Clinical evaluation of haploidentical hematopoietic combined with human umbilical cord-derived mesenchymal stem cells in severe aplastic anemia.

Authors:  Lixin Xu; Zhouyang Liu; Yamei Wu; Xueliang Yang; Yongbin Cao; Xiaohong Li; Bei Yan; Songwei Li; Wanming Da; Xiaoxiong Wu
Journal:  Eur J Med Res       Date:  2018-03-01       Impact factor: 2.175

6.  The Addition of Sirolimus to GVHD Prophylaxis After Allogeneic Hematopoietic Stem Cell Transplantation: A Meta-Analysis of Efficacy and Safety.

Authors:  Xiaoli Chen; Hengrui Sun; Kaniel Cassady; Shijie Yang; Ting Chen; Li Wang; Hongju Yan; Xi Zhang; Yimei Feng
Journal:  Front Oncol       Date:  2021-09-09       Impact factor: 6.244
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.